Helius Medical Technologies
190 articles about Helius Medical Technologies
-
Helius Medical Technologies, Inc. Launches New Website for U.S.-Based Patients and Physicians
8/11/2021
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that the Company has launched a new website: https://ponstreatment.com, created to serve as a resource for U.S.-based patients and physicians.
-
Helius Medical Technologies, Inc. to Present at Two Upcoming Investor Conferences in July
7/12/2021
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the following upcoming investor conferences in July:
-
Helius Medical Technologies, Inc. Appoints Antonella Favit-Van Pelt, M.D., Ph.D. as Chief Medical Officer
7/8/2021
Helius Medical Technologies, Inc. today announced the appointment of Antonella Favit-Van Pelt, M.D., Ph.D. to the position of Chief Medical Officer.
-
Helius Medical Technologies, Inc. to Participate in the Annual World Congress of the Society for Brain Mapping and TherapeuticsCompany Selected to Receive the “Pioneer in Technology Award”
7/7/2021
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced it will participate in the Annual World Congress of the Society for Brain Mapping and Therapeutics, which will be held from July 8-11th in Los Angeles, California.
-
Helius Medical Technologies, Inc. to Release Second Quarter of Fiscal Year 2021 Financial Results on August 12, 2021
6/30/2021
Helius Medical Technologies, Inc. today announced that second quarter of fiscal year 2021 financial results will be released after the market closes on Thursday, August 12th.
-
Helius Medical Technologies, Inc. Expands Executive Leadership Team with the Appointment of Dane C. Andreeff as President and Chief Executive Officer and Jeffrey S. Mathiesen as Chief Financial Officer
6/15/2021
Helius Medical Technologies, Inc. today announced that Dane C. Andreeff and Jeffrey S. Mathiesen have been appointed to the respective positions of President and Chief Executive Officer and Chief Financial Officer, effective June 14, 2021.
-
Helius Medical Technologies, Inc. to Participate in Noble Capital Markets’ Virtual Road Show Series
6/8/2021
Helius Medical Technologies, Inc. today announced its participation in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek, which is scheduled for Thursday, June 10, 2021.
-
Helius Medical Technologies, Inc. Appoints Frederick Fantazzia as Vice President of Sales & Marketing, North America
6/2/2021
Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, announced the appointment of Frederick Fantazzia to the position of Vice President of Sales & Marketing, North America, effective June 1, 2021.
-
Helius Medical Technologies, Inc. Reports First Quarter 2021 Financial Results
5/17/2021
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter ended March 31, 2021.
-
Helius Medical Technologies, Inc. to Present at the Planet MicroCap Showcase on April 21st
4/15/2021
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the Planet MicroCap Showcase, which is being held virtually from April 20th-22nd.
-
Helius Medical Technologies, Inc. to Release First Quarter of Fiscal Year 2021 Financial Results on May 17, 2021
4/7/2021
Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that first quarter of fiscal year 2021 financial results will be released after the market closes on Monday, May 17th. Management will host a conference call at 5:00 p.m. Eastern Time on May 17th to discuss the results of the quarter and fiscal year.
-
Helius Medical, Inc Receives U.S. Marketing Authorization for the PoNS™ Device
3/29/2021
First and only tongue-delivered neuromodulation therapy provides new treatment option for U.S. patients living with gait deficit due to symptoms from multiple sclerosis
-
Helius Medical Technologies, Inc. to Present at the Investor Summit Group’s Q1 Virtual Summit on March 23rd
3/17/2021
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the Investor Summit Group’s Q1 Virtual Summit, which is being held from March 23th-25th.
-
Helius Medical Technologies, Inc. Appoints Sherrie Perkins to its Board of Directors
3/17/2021
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the appointment of Sherrie Perkins, effective March 15, 2021.
-
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results
3/10/2021
Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, reported financial results for the quarter and full year ended December 31, 2020.
-
Helius Medical Technologies to Release Fourth Quarter and Fiscal Year 2020 Financial Results on March 10, 2021
2/2/2021
Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that fourth quarter and fiscal year 2020 financial results will be released after the market closes on Wednesday, March 10th. Management will host a conference call at 5:00 p.m. Eastern Time on March 10th to discuss the results of the quarter and fiscal year.
-
Helius Medical Technologies, Inc. Announces Closing of $11.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
2/1/2021
Helius Medical Technologies, Inc, announced today the closing of an underwritten public offering of units for gross proceeds of approximately $11.0 million, which includes the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Helius.
-
Helius Medical Technologies, Inc. Announces Pricing of $9.6 Million Underwritten Public Offering Priced At Market
1/28/2021
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced today announced the pricing of an underwritten public offering of units for gross proceeds of approximately $9.6 million prior to deducting underwriting discounts and commissions and offering expenses payable by Helius.
-
Helius Medical Technologies, Inc. Comments on the Centers for Medicare & Medicaid Services’ Announcement Regarding New Medicare Coverage Pathway for Breakthrough Medical Devices
1/20/2021
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today provided comments in response to a press release issued by the Centers for Medicare & Medicaid Services (“CMS”) on Tuesday, January 12, 2021.
-
Helius Medical Technologies, Inc. Regains Compliance with Nasdaq Listing Standards
1/19/2021
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that it received written notice from The Nasdaq Stock Market LLC that the Company’s minimum bid price deficiency has been cured, and that the Company is in compliance with all applicable listing standards